The PI3K p110δ Isoform Inhibitor Idelalisib Preferentially Inhibits Human Regulatory T Cell Function

FOXP3, the Transcription Factor at the Heart of the Rebirth of Immune Tolerance

(2017) Jeffrey A. Bluestone   JOURNAL OF IMMUNOLOGY

Idelalisib given front-line for treatment of chronic lymphocytic leukemia causes frequent immune-mediated hepatotoxicity

(2016) B. L. Lampson et al.   BLOOD

Outcomes of patients with chronic lymphocytic leukemia treated with first-line idelalisib plus rituximab after cessation of treatment for toxicity

(2016) Philip A. Thompson et al.   CANCER

AKT isoforms modulate Th1‐like Treg generation and function in human autoimmune disease

(2016) Alexandra Kitz et al.   EMBO REPORTS

Phosphatidylinositol 3-Kinase p110δ Isoform Regulates CD8+T Cell Responses during Acute Viral and Intracellular Bacterial Infections

(2016) Donald T. Gracias et al.   JOURNAL OF IMMUNOLOGY

Targeting PI3K in Cancer: Impact on Tumor Cells, Their Protective Stroma, Angiogenesis, and Immunotherapy

(2016) K. Okkenhaug et al.   Cancer Discovery

Idelalisib: First-in-Class PI3K Delta Inhibitor for the Treatment of Chronic Lymphocytic Leukemia, Small Lymphocytic Leukemia, and Follicular Lymphoma

(2015) Q. Yang et al.   CLINICAL CANCER RESEARCH

The interplay of effector and regulatory T cells in cancer

(2015) Rahul Roychoudhuri et al.   CURRENT OPINION IN IMMUNOLOGY

PI3K inhibitors in inflammation, autoimmunity and cancer

(2015) Anne-Katrien Stark et al.   CURRENT OPINION IN PHARMACOLOGY

PI3Kδ Regulates the Magnitude of CD8+T Cell Responses after Challenge withListeria monocytogenes

(2015) Verity Q. Pearce et al.   JOURNAL OF IMMUNOLOGY

Human regulatory T cells control TCR signaling and susceptibility to suppression in CD4+ T cells

(2015) Stalin Chellappa et al.   JOURNAL OF LEUKOCYTE BIOLOGY

Management of adverse events associated with idelalisib treatment: expert panel opinion

(2015) Steven E. Coutré et al.   LEUKEMIA & LYMPHOMA

Treg cells require the phosphatase PTEN to restrain TH1 and TFH cell responses

(2015) Sharad Shrestha et al.   NATURE IMMUNOLOGY

Control of PI(3) kinase in Treg cells maintains homeostasis and lineage stability

(2015) Alexandria Huynh et al.   NATURE IMMUNOLOGY

Prognostic value of tumor-infiltrating FoxP3+ regulatory T cells in cancers: a systematic review and meta-analysis

(2015) Bin Shang et al.   Scientific Reports

Immunomodulation of Selective Naive T Cell Functions by p110δ Inactivation Improves the Outcome of Mismatched Cell Transplantation

(2015) Jean-Marc Doisne et al.   Cell Reports

Akt Inhibition Enhances Expansion of Potent Tumor-Specific Lymphocytes with Memory Cell Characteristics

(2014) J. G. Crompton et al.   CANCER RESEARCH

Continuous T Cell Receptor Signals Maintain a Functional Regulatory T Cell Pool

(2014) J. Christoph Vahl et al.   IMMUNITY

Inactivation of PI(3)K p110δ breaks regulatory T-cell-mediated immune tolerance to cancer

(2014) Khaled Ali et al.   NATURE

Continuous requirement for the TCR in regulatory T cell function

(2014) Andrew G Levine et al.   NATURE IMMUNOLOGY

Selective Inhibition of Regulatory T Cells by Targeting the PI3K-Akt Pathway

(2014) R. Abu-Eid et al.   Cancer Immunology Research

Signaling by the Phosphoinositide 3-Kinase Family in Immune Cells

(2013) Klaus Okkenhaug   Annual Review of Immunology

Modulating T regulatory cells in cancer: how close are we?

(2013) Ashish Banerjee et al.   IMMUNOLOGY AND CELL BIOLOGY

An obligate cell-intrinsic function for CD28 in Tregs

(2013) Ruan Zhang et al.   JOURNAL OF CLINICAL INVESTIGATION

The Prognostic Value of FoxP3+ Tumor-Infiltrating Lymphocytes in Cancer: A Critical Review of the Literature

(2012) R. J. deLeeuw et al.   CLINICAL CANCER RESEARCH

Naturally occurring regulatory T cells: markers, mechanisms, and manipulation

(2012) Klaus G. Schmetterer et al.   FASEB JOURNAL

Therapeutic opportunities for manipulating TReg cells in autoimmunity and cancer

(2012) Harald von Boehmer et al.   NATURE REVIEWS DRUG DISCOVERY

Does the PI3K pathway promote or antagonize regulatory T cell development and function?

(2012) Dalya R. Soond et al.   Frontiers in Immunology

Resolving the identity myth: Key markers of functional CD4+FoxP3+ regulatory T cells

(2011) Xin Chen et al.   INTERNATIONAL IMMUNOPHARMACOLOGY

T Cell-Signaling Network Analysis Reveals Distinct Differences between CD28 and CD2 Costimulation Responses in Various Subsets and in the MAPK Pathway between Resting and Activated Regulatory T Cells

(2011) Maria Elisabeth Kalland et al.   JOURNAL OF IMMUNOLOGY

The PI3K p110δ Regulates Expression of CD38 on Regulatory T Cells

(2011) Daniel T. Patton et al.   PLoS One

Cancer Immunoediting: Integrating Immunity's Roles in Cancer Suppression and Promotion

(2011) R. D. Schreiber et al.   SCIENCE

PI3K p110  regulates T-cell cytokine production during primary and secondary immune responses in mice and humans

(2010) D. R. Soond et al.   BLOOD

T regulatory cells in cancer: recent advances and therapeutic potential

(2010) Eyad Elkord et al.   EXPERT OPINION ON BIOLOGICAL THERAPY

Phosphoinositide 3-Kinase Activity in T Cells Regulates the Magnitude of the Germinal Center Reaction

(2010) J. Rolf et al.   JOURNAL OF IMMUNOLOGY

B-cell signaling networks reveal a negative prognostic human lymphoma cell subset that emerges during tumor progression

(2010) J. M. Irish et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

T Cell Activation

(2009) Jennifer E. Smith-Garvin et al.   Annual Review of Immunology

MAPK, Phosphatidylinositol 3-Kinase, and Mammalian Target of Rapamycin Pathways Converge at the Level of Ribosomal Protein S6 Phosphorylation to Control Metabolic Signaling in CD8 T Cells

(2009) R. J. Salmond et al.   JOURNAL OF IMMUNOLOGY

The p110  Isoform of Phosphatidylinositol 3-Kinase Controls Susceptibility to Leishmania major by Regulating Expansion and Tissue Homing of Regulatory T Cells

(2009) D. Liu et al.   JOURNAL OF IMMUNOLOGY